Skip to main content
Journal cover image

Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.

Publication ,  Journal Article
Sandborn, WJ; Bhandari, BR; Fogel, R; Onken, J; Yen, E; Zhao, X; Jiang, Z; Ge, D; Xin, Y; Ye, Z; French, D; Silverman, JA; Kanwar, B ...
Published in: Aliment Pharmacol Ther
July 2016

BACKGROUND: Matrix metalloproteinase-9 is a proteolytic enzyme whose expression is increased in ulcerative colitis. AIM: To evaluate the safety and efficacy of GS-5745, a fully humanised anti-matrix metalloproteinase-9 monoclonal antibody, in moderately-to-severely active ulcerative colitis. METHODS: We randomised 74 patients with ulcerative colitis to treatment with single or multiple ascending intravenous or subcutaneous doses of GS-5745 or placebo. Multiple-dose cohorts received either IV infusions (0.3, 1.0, 2.5 or 5.0 mg/kg GS-5745 or placebo) every 2 weeks (three total IV infusions) or five weekly SC injections (150 mg GS-5745 or placebo). The primary outcomes were the safety, tolerability and pharmacokinetics of escalating single and multiple doses of GS-5745. Exploratory analyses in the multiple-dose cohorts included clinical response (≥3 points or 30% decrease from baseline in Mayo Clinic score and ≥1 point decrease in the rectal bleeding subscore or a rectal bleeding subscore ≤1) and clinical remission (a complete Mayo Clinic score ≤2 with no subscore >1) at Day 36. Biological effects associated with a clinical response to GS-5745 were explored using histological and molecular approaches. RESULTS: Twenty-three of the 42 patients (55%) receiving multiple doses of GS-5745 had adverse events, compared with 5/8 patients (63%) receiving placebo. GS-5745 showed target-mediated drug disposition, approximately dose-proportional increases in maximum plasma concentration and more than dose-proportional increases in the area under the plasma drug concentration-time curve. Clinical response occurred in 18/42 patients (43%) receiving GS-5745 compared with 1/8 patients (13%) receiving placebo. Clinical remission occurred in 6/42 patients (14%) receiving GS-5745 and 0/8 (0%) receiving placebo. Patients with a clinical response to GS-5745 had reductions in matrix metalloproteinase-9 tissue levels (mean 48.9% decrease from baseline compared with a mean 18.5% increase in nonresponders, P = 0.008) significant improvements in histopathology scores (confirmed with three separate histological disease activity indices), as well as changes in colonic gene expression that were consistent with reduced inflammation. CONCLUSION: This phase 1 trial provides preliminary evidence for the safety and therapeutic potential of GS-5745 in the treatment of ulcerative colitis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Aliment Pharmacol Ther

DOI

EISSN

1365-2036

Publication Date

July 2016

Volume

44

Issue

2

Start / End Page

157 / 169

Location

England

Related Subject Headings

  • Treatment Outcome
  • Middle Aged
  • Matrix Metalloproteinase 9
  • Male
  • Infusions, Intravenous
  • Humans
  • Gastroenterology & Hepatology
  • Female
  • Dose-Response Relationship, Drug
  • Colitis, Ulcerative
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sandborn, W. J., Bhandari, B. R., Fogel, R., Onken, J., Yen, E., Zhao, X., … Feagan, B. G. (2016). Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther, 44(2), 157–169. https://doi.org/10.1111/apt.13653
Sandborn, W. J., B. R. Bhandari, R. Fogel, J. Onken, E. Yen, X. Zhao, Z. Jiang, et al. “Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.Aliment Pharmacol Ther 44, no. 2 (July 2016): 157–69. https://doi.org/10.1111/apt.13653.
Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, et al. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 Jul;44(2):157–69.
Sandborn, W. J., et al. “Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.Aliment Pharmacol Ther, vol. 44, no. 2, July 2016, pp. 157–69. Pubmed, doi:10.1111/apt.13653.
Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 Jul;44(2):157–169.
Journal cover image

Published In

Aliment Pharmacol Ther

DOI

EISSN

1365-2036

Publication Date

July 2016

Volume

44

Issue

2

Start / End Page

157 / 169

Location

England

Related Subject Headings

  • Treatment Outcome
  • Middle Aged
  • Matrix Metalloproteinase 9
  • Male
  • Infusions, Intravenous
  • Humans
  • Gastroenterology & Hepatology
  • Female
  • Dose-Response Relationship, Drug
  • Colitis, Ulcerative